December 21 2022, BioNTech announced they had dosed the first clinical trial participant. This is the first-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163.
Company statement; “We aim to help address diseases with a high unmet medical need and of global health relevance, and we are combining our new technologies such as #mRNA and our expertise in immune engineering. As part of our strategy, we have announced that the first subject was dosed in a first-in-human Phase 1 clinical trial with BNT163, a prophylactic herpes simplex virus-2 vaccine candidate. The program is part of our collaboration with the University of Pennsylvania.”
Trials are active and currently recruiting for health volunteers without HSV infection.
Locations are currently open in North Carolina, with more locations to be added.
Apply to participate in clinical trial for herpes vaccine
Read more in the news:
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
SPECIAL EVENT: Meet the Experts
Meet the Experts w/Dr. Harvey Friedman
January 11, 2023, 6pm EST
Register today for live Q&A with Dr. Harvey Friedman to learn more about his research and plans for this clinical trial with BioNtech.
One thought on “BioNTech New Clinical Trial for Herpes Vaccine begins”